ChemicalBook > Product Catalog > API > Digestive system drugs > Antacid and Mucosal protective Drugs > R-(+)-Lansoprazole
R-(+)-Lansoprazole Chemical Properties
- Melting point:66-68?C
- Boiling point:555.8±60.0 °C(Predicted)
- Density 1.50±0.1 g/cm3(Predicted)
- storage temp. Refrigerator
R-(+)-Lansoprazole Usage And Synthesis
- DescriptionThe mechanism of PPIs involves the irreversible binding to the hydrogen/potassium adenosine triphosphatase enzyme system, commonly referred to as the gastric proton pump, of the gastric parietal cell. As the last stage in gastric acid secretion, blockade of the gastric proton pump is an effective treatment for a variety of diseases requiring acid suppression, such as heartburn, peptic ulcers, and GERD. Dexlansoprazole is the latest PPI to hit the market, joining the ranks of omeprazole, rabeprazole, pantoprazole, esomeprazole, and lansoprazole, and is the Renantiomer of the racemic lansoprazole. Compared to its predecessors, dexlansoprazole exhibits improved pharmacokinetics with slower clearance and longer terminal half-life. In addition, dexlansoprazole utilizes a novel DDR technology; drug release is optimized through the use of granules with different pH-dependent dissolution profiles, thereby providing an initial release in the proximal small intestine within 1-2 h of administration followed by a subsequent release at distal regions of the small intestine several hours later. With its longer duration of action culminating in more effective acid suppression, dexlansoprazole may have an advantage over conventional PPIs that possess single release formulations (immediate or delayed). Similar to all PPIs, dexlansoprazole is a prodrug that consists of pyridine and benzimidazole rings with a latent sulfenamide moiety. In order to form the disulfide bond with cysteine residues of the proton pump, dexlansoprazole must be activated through two protonations followed by a spontaneous rearrangement to unmask the sulfenamide.
- Chemical PropertiesBrown Solid
- OriginatorTakeda (Japan)
- UsesThe R-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative
- Usesantiulcer, proton pump inhibitor
- UsesActs as a gastric proton pump inhibitor and an antiulcerative
- brand nameKapidex
- Side effectsThe most commonly recorded adverse reactions that occurred at a higher incidence than placebo were diarrhea, abdominal pain, nausea, vomiting, flatulence, and upper respiratory tract infection. As dexlansoprazole inhibits gastric acid secretion, its use is expected to interfere with the absorption of drugs with pH-dependent oral bioavailability. Since the HIV protease inhibitor atazanavir is dependent on gastric acid for absorption, dexlansoprazole should not be co-administered with atazanavir to avoid a loss of therapeutic efficacy. While co-administration of dexlansoprazole did not affect the pharmacokinetics of warfarin or INR (international normalized ratio: the ratio of a patient s prothrombin time to a normal sample), there have been reports of increased INR and prothrombin time in patients receiving concomitant treatment with PPIs and warfarin. Since increases in INR and prothrombin time may lead to abnormal bleeding and possibly death, concomitant use of dexlansoprazole and warfarin may necessitate monitoring for increases in INR and prothrombin time.
- Company Name:Shanghai Huilun Life Science&Technology Co.Ltd. Gold
- Company Name:Lihe Wuhan New Chemical Materials Co., Ltd. Gold
- Company Name:Shanghai Boyle Chemical Co., Ltd.
- Company Name:SiChuang NanBu Honesty Technology Co., Ltd.
- Tel:15883665058 0838-5675166
- Company Name:J & K SCIENTIFIC LTD.
- Tel:400-666-7788 010-82848833-